Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
Motif Bio Granted Meeting with U.S. FDA regarding Iclaprim
March 20, 2019
Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the U.S. Food & Drug Administration (FDA) has granted the Company’s request for a Type A meeting to discuss the points raised in the Complete Response Letter received from the FDA related to the New Drug Application (NDA) for iclaprim for the treatment of acute bacterial skin and skin structure infections. The meeting is scheduled to take place on Ma... Read More
Motif Bio Announces Appointment of Bruce Williams as Interim Chairman and Resignation of Richard Morgan from the Board
March 18, 2019
NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Richard C. E. Morgan has tendered his resignation as Non-executive Chairman and is stepping down from the Board of Directors, effective immediately, to focus on other business commitments. Bruce Williams, a long-standing Board member, has been appointed Interim Chairman. Mr. Morgan has agreed to remain availab... Read More
Motif Bio Conference Call and Webcast
February 19, 2019
NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company will hold a conference call on Tuesday, February 19, 2019 at 8:30 AM ET/1:30 PM GMT/2:30 PM CET.  The call will be held to discuss recent events that Motif has announced and the Company’s plans. No new material information will be disclosed during the call. The dial-in details are as follows: ... Read More
Motif BioSciences Enters into Amendment Agreement with Hercules Capital
February 18, 2019
NEW YORK, Feb. 18, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Motif BioSciences Inc. (a wholly owned subsidiary) has entered into an amendment agreement with its lender Hercules Capital, Inc (NYSE:HTGC) (“Hercules”) in relation to the loan agreement as notified on 15 November 2017. Pursuant to the amendment, Motif BioSciences Inc. will make an immediate early repayme... Read More
Motif Bio Receives Complete Response Letter from the FDA
February 14, 2019
NEW YORK, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) regarding the New Drug Application (NDA) for iclaprim for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The CRL states that the FDA cannot approve the NDA in its present... Read More